Gyrolab Anti-AAVX Kit | All serotypes | Automated Immunoassays

Pre-existing antibodies against AAV are a major hurdle making it hard to predict immune responses and ensure valid results in preclinical studies. To prevent risks of data reliability and study models, it is necessary to assess levels of pre-existing AAV immunogenicity antibodies in potential candidates between and within species before inclusion in clinical trials.

Traditional assays demand weeks of serotype-specific development, wasting time and resources you can’t afford to lose.

Capsid labeling adds unnecessary complexity, introducing variability and limiting reproducibility across batches. High capsid consumption drains critical materials needed for commercialization, slowing down your path to market.

Without clear regulatory guidelines, labs are left to shoulder the burden of proving assay robustness, adding pressure and uncertainty.

The result? Delayed timelines, higher costs, and reduced productivity in a fast-moving industry.

It’s time for a smarter, faster and more reliable approach to anti-AAV testing.